Therapeutic drug monitoring of nevirapine in resource-limited settings

Clinical Infectious Diseases

Volumn 47, Issue 10, 2008, Pages 1339-1344

  L'Homme, Rafaëlla F A ^a   Muro, Eva P ^b   Droste, Jacqueline A H ^a   Wolters, Liselotte R ^b   Van Ewijk Beneken Kolmer, Noor W J ^a   Schimana, Werner ^b   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SALIVA LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY;

ADOLESCENT; ADULT; AFRICA; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; DRUG MONITORING; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; PLASMA; SALIVA; SENSITIVITY AND SPECIFICITY;

EID: 54249134314     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/592694     Document Type: Article

References (12)

1. Vries-Sluijs TE, Dieleman JP, Arts D, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003; 42:599-605.
2. Veldkamp AI, Weverling GJ, Lange JMA, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15:1089-95.
3. La Porte CJ, Back DJ, Blaschke T, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 2006; 3:4-14.
4. van Heeswijk RP, Veldkamp AI, Mulder JW, et al. Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine. Ther Drug Monit 2001; 23:255-8.
5. Muro E, Droste JA, Hofstede HT, Bosch M, Dolmans W, Burger DM. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J Acquir Immune Defic Syndr 2005; 39:419-21.
6. Hollanders RMW, van Ewijk-Beneken Kolmer EWJ, et al. Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000; 744:65-71.
7. Fleiss JL. Measuring nominal scale agreement among many raters. Psychological Bulletin 1971; 76:378-82.
8. Cohen J. A coefficient for agreement for nominal scales. Educ Psychol Meas 1960; 20:37-46.
9. Dubuisson JG, King JR, Stringer JS, Turner ML, Bennetto C, Acosta EP. Detection of nevirapine in plasma using thin-layer chromatography. J Acquir Immune Defic Syndr 2004; 35:155-7.
10. Van Oosterhout JJ, Bodasing N, Kumwenda JJ, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 2005; 10:464-70.
11. L'homme RFA, Dijkema T, van der Ven AJAM, Burger DM. Enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. J Acquir Immune Defic Syndr 2006; 43:193-6.
12. Rakhmanina NY, Capparelli EV, van den Anker JN, et al. Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection. Ther Drug Monit 2007; 29:110-7.